DigestRedComo funciona
Red
/
Empresas
Br
No verificado

Bristol Myers Squibb

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

107 Comunicados de prensa

Ver todos los comunicados de prensa
05/12/2025
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
03/12/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
01/12/2025
Eventos
Ferias y Congresos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
26/11/2025
Eventos
Biotecnología
Farmacéutica
Salud
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
24/11/2025
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
24/11/2025
Web y redes sociales
Eventos
Biotecnología
Farmacéutica
Salud
Bristol Myers Squibb to Host Hematology-Focused Investor Event
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
18/11/2025
Finanzas
Biotecnología
Farmacéutica
Salud
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
18/11/2025
Biotecnología
Finanzas
Salud
Asociaciones/Profesionales
Farmacéutica
Acciones y Obligaciones
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
14/11/2025
Mercado laboral
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Update on Phase 3 Librexia ACS Trial
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
05/11/2025
Biotecnología
Farmacéutica
Salud
Oncología
Acciones y Obligaciones
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0